COMPANY:

EntroGen

"EntroGen, Inc. announces the immediate availability of its new NGS Targeted Hotspot Panel (THSP) designed to detect the most clinically relevant hotspot mutations in 16 genes across diverse tumor types. The panel is compatible with Illumina® MiniSeq, MiSeq and NexSeq 500. The company is obtaining a CE-IVD marking in the EU for the NGS Targeted Hotspot Panel. It is currently available worldwide for research use only."

"EntroGen Inc. announced that it has entered into a clinical collaboration with University of Southern California Norris Comprehensive Cancer Center to conduct an observational study to determine the clinical utility of EntroGen’s liquid biopsy solutions for lung cancer patients. The year-long study will assess and monitor the levels of EGFR activating and resistance mutations in the blood of patients diagnosed with non-small cell lung cancer who are undergoing EGFR TKI therapy. EntroGen’s ctEGFR test is a real-time polymerase chain reaction (PCR) test that identifies EGFR TKI sensitizing and acquired resistance mutations from as little as one milliliter of plasma. The test utilizes proprietary technology to enable ultra-sensitive detection of mutant variants on a background of normal circulating cell-free DNA."